Peptide T: What It Is and Current Research

Key Takeaways

• What it is: A synthetic octapeptide (D-Ala-Peptide T-amide, or DAPTA) originally identified by NIH scientist Candace Pert as a potential blocker of gp120-mediated neurotoxicity in HIV.
• Mechanism: Binds the CCR5 co-receptor at nanomolar concentrations and blocks gp120-CCR5 interaction in laboratory assays; proposed, in preclinical models, to reduce gp120-mediated neuronal apoptosis — a mechanistic hypothesis that was not confirmed by clinical trial outcomes.
• Clinical trial result: The principal RCT by Heseltine and colleagues (1998) found no overall cognitive advantage versus placebo in HIV-positive individuals; subgroup signals were not pre-specified.
• Regulatory status: As of April 2026, not FDA-approved for any indication. Not on any FDA bulk drug substance compounding list. Not available through Superpower.
• Research relevance: CCR5-targeted neuroprotection remains an active research area; Peptide T is cited in the literature as a historical reference compound in this mechanistic class.

What Peptide T Is and Where It Comes From

Peptide T is a synthetic octapeptide — eight amino acids in length — derived from a sequence found in the HIV envelope protein gp120. The compound is more precisely designated D-Ala-Peptide T-amide (DAPTA), reflecting a D-alanine substitution at the N-terminus and C-terminal amidation that improve its metabolic stability. The original sequence was identified in the early 1980s by Candace Pert, a neuroscientist at the National Institutes of Health, during investigation of the structural overlap between the HIV gp120 envelope protein and the vasoactive intestinal peptide (VIP) receptor. Pert, profiled in a 2003 interview in Molecular Interventions, described the receptor pharmacology and HIV biology convergence that led to the Peptide T hypothesis: if gp120 engages the same receptor sites as VIP-class neuropeptides, a short peptide derived from gp120 might competitively block that interaction and prevent neuronal death.

Discovery and history

The compound emerged from a specific scientific question: why does HIV damage neurons, which do not themselves express CD4, the canonical HIV entry receptor? Brenneman and colleagues, writing in Advances in Neuroimmunology in 1994, described foundational work showing that HIV gp120 kills hippocampal neurons and in animal models — and that Peptide T prevented this gp120-induced neurotoxicity. That finding defined the therapeutic hypothesis that drove clinical development through the 1990s and early 2000s.

How Peptide T Works: The CCR5 Mechanism

The proposed mechanism of Peptide T centers on CCR5, a chemokine co-receptor expressed on neurons and immune cells. CCR5, alongside CXCR4, is one of two principal co-receptors that HIV uses to enter host cells in combination with CD4. R5-tropic strains of HIV (which use CCR5) are the predominant strains in early HIV infection and in CNS reservoirs.

CCR5 binding and gp120 blockade

Polianova and colleagues, publishing in Antiviral Research in 2005, reported that DAPTA inhibited gp120 binding to CCR5 with an IC50 of ~0.06 nM, and co-immunoprecipitation and confocal-microscopy studies identified CCR5 as a DAPTA receptor. The selective activity against R5-tropic strains explains a critical gap in earlier studies: trials that used X4-tropic viral strains (which use CXCR4, not CCR5) would not have detected antiviral activity. Ruff and colleagues, in their 2003 review in Current HIV Research, clarified this strain-selectivity issue and reframed it as a key reason why the CCR5 mechanism was underappreciated in early research.

Neuroprotection: blocking macrophage-mediated neuronal apoptosis

HIV replication in the CNS occurs primarily within macrophages and microglia rather than neurons directly. These infected cells release neurotoxic factors — including viral proteins, cytokines, and excitatory amino acids — that drive neuronal apoptosis. Pollicita and colleagues, publishing in Antiviral Chemistry and Chemotherapy in 2007, reported that DAPTA inhibited R5 HIV-1 replication in macrophages by more than 90% at nanomolar concentrations and protected neurons from macrophage-mediated apoptosis in ex vivo models; within those preclinical ex vivo assays, the reported neuroprotective endpoints for DAPTA exceeded those reported for the CCR5 antagonist TAK-779. These are preclinical comparative findings within a single study and do not establish comparative clinical efficacy. Bachis and Mocchetti, in a 2009 review in the Journal of NeuroImmune Pharmacology, showed that both R5 and X4 HIV strains induce neuronal apoptosis through envelope protein signaling, providing ongoing rationale for CCR5-targeted neuroprotection.

Chemokine pathway modulation beyond HIV

Peptide T's activity extends to chemokine receptor signaling outside the viral entry context. Raychaudhuri and colleagues, in a 1998 study in the International Journal of Immunopharmacology, demonstrated that DAPTA significantly inhibited monocyte and lymphocyte chemotaxis toward RANTES, a chemokine that signals through CCR5. This anti-chemotactic activity provided a mechanistic basis for the observed effects in psoriasis, where inflammatory cell trafficking is a central pathological process. Tufano and colleagues, in a 2002 mechanistic study in the British Journal of Dermatology, showed that Peptide T reduced ICAM-1 expression, upregulated TGF-β and HSP-70, and normalized keratinocyte proliferation, supporting the proposed anti-inflammatory profile in skin.

Structural Biology of Peptide T

Peptide T's eight amino acid sequence adopts a flexible conformation in solution, with a tendency toward beta-turn and gamma-turn structures that are proposed to correlate with its receptor-binding activity. De Dios and colleagues, in a 2004 NMR study in the Journal of Peptide Science, identified conformational heterogeneity and potential beta-sheet aggregation at higher concentrations — a finding relevant to formulation and dosing stability. D'Ursi and colleagues, in a 2007 structure-activity study in the same journal, showed that the beta- and gamma-turn conformations correlate with chemotactic-blocking activity, providing a structural framework for analog design.

• Peptide T (original sequence)
  • Key structural feature: Eight amino acids; flexible, beta-turn-prone conformation in solution
  • Primary mechanism: gp120-CCR5 interaction blockade; showed neuroprotective activity in preclinical HIV model systems
  • Where the research stands: Historical reference compound; no FDA approval; clinical trial did not meet primary endpoint
• DAPTA (D-Ala-Peptide T-amide)
  • Key structural feature: D-alanine N-terminal substitution and C-terminal amidation for improved metabolic stability
  • Primary mechanism: CCR5 selective binding at IC50 ~0.06 nM; R5-tropic HIV suppression
  • Where the research stands: Primary form used in clinical trials; same regulatory status as Peptide T

Gkogka and colleagues, in a 2022 computational study in the Journal of Computational Chemistry, confirmed Peptide T's preferred beta-turn structure and flexible dynamics using modern computational methods — work that matches the earlier NMR data and could inform future analog development.

What the Clinical Evidence Shows

The clinical evidence base for Peptide T is anchored by two randomized controlled trials, both in HIV-positive populations, both studying intranasal administration, and both failing to demonstrate statistically significant overall cognitive benefit.

The Heseltine RCT (1998): the primary clinical trial

The trial by Heseltine and colleagues, published in Archives of Neurology in 1998, is the primary clinical evidence statement for Peptide T. The study tested intranasal Peptide T versus placebo in HIV-positive individuals for cognitive outcomes. As reported, the trial found no advantage over placebo on the primary cognitive endpoints. Subgroup analyses suggested potential benefit in patients who were more cognitively impaired at baseline or immunologically preserved — but these analyses were not pre-specified and do not meet the evidentiary standard for a primary efficacy claim. The overall outcome of the trial remains the most important single fact about Peptide T's clinical history.

The Goodkin multisite RCT (2006)

Goodkin and colleagues, in a multisite randomized controlled trial published in the Journal of NeuroVirology in 2006, showed that intranasal Peptide T reduced peripheral HIV load without CSF changes and did not produce overall cognitive benefit. The dissociation between peripheral and CSF viral load reduction is a mechanistically important finding: it suggests Peptide T may affect peripheral R5-tropic viral compartments without achieving effective CNS concentrations — which would limit its neuroprotective potential regardless of the mechanistic rationale in cell-culture and animal models.

The small open-label study and immunologic signals

Polianova and colleagues, in a 2003 open-label study of 11 long-term HIV patients published in Peptides, reported that intranasal Peptide T did not lower plasma HIV RNA but was associated with CD4 count increases in 5 of 11 patients, a fourfold rise in interferon-gamma-secreting T cells, and reduced monocyte viral reservoir. No treatment-emergent adverse events were reported in this small open-label cohort, but the sample size is insufficient to characterize a safety profile. This is an open-label study with eleven participants — its findings are hypothesis-generating, not confirmatory, and cannot be cited as clinical efficacy or safety evidence.

Evidence limitations

Phillips and colleagues, in a 2010 systematic review and meta-analysis published in PLoS One that evaluated RCT evidence for painful HIV-associated sensory neuropathy, found no superiority over placebo for peptide T (6 mg/day) alongside eight other agents. As of April 2026, no completed Phase 3 human trial of Peptide T for any indication has been published. The compound's mechanistic rationale — CCR5 blockade for neuroprotection — is scientifically coherent; the clinical data do not confirm it translates to meaningful benefit in adequately powered trials. Understanding where your own inflammatory and immune markers stand provides more actionable data than the mechanistic literature on this compound alone. Baseline high-sensitivity CRP and immune function panels provide objective context for any discussion of neuroinflammatory biology.

Broader Context: CCR5 Neuroprotection as a Research Area

Despite the clinical trial outcomes for Peptide T specifically, CCR5-targeted neuroprotection remains an active research area. Kuhn and colleagues, publishing in Biomedicines in 2024, provided recent evidence that chemokine receptor antagonists protect neurons against HIV-related synaptic pathology in cultured rodent and human iPSC-derived neurons, with CCR5 among the targets studied. Gao and colleagues, in a 2019 paper in Pathobiology, demonstrated the breadth of CCR5-mediated injury beyond neurons, supporting continued interest in CCR5 blockade as a neuroprotective strategy. The category-level research continues; Peptide T itself is a historical compound within that category, not a current clinical development candidate.

Reported Endocrine and Dermatologic Research Directions

Two secondary research directions have appeared in the Peptide T literature, each with very limited data. Mulroney and colleagues, in a 1998 PNAS study, demonstrated that gp120 disrupts GHRH signaling, providing a mechanism for AIDS wasting and a rationale for Peptide T's reported growth hormone effects. Barbey-Morel and colleagues, in a 2002 case series in Peptides, described two pediatric AIDS patients in whom Peptide T normalized disordered GH secretion — a report involving two patients that cannot support conclusions about efficacy.

The dermatologic literature, summarized above, involves Johansson and colleagues' 1994 skin biopsy study in Acta Dermato-Venereologica showing changes in somatostatin-positive cells during Peptide T treatment of psoriasis, and the subsequent mechanistic work by Tufano and Raychaudhuri. None of this work produced an FDA-reviewed indication or an adequately powered randomized trial in psoriasis.

How This Connects to Measurable Biomarkers

For anyone interested in the neuroimmunology and HIV-related biology relevant to Peptide T's proposed mechanisms, the following markers provide objective, testable context. These are standard clinical measures unrelated to Peptide T's availability or status.

• High-sensitivity CRP: A systemic inflammatory marker relevant to the neuroinflammatory biology underlying neuroAIDS and CCR5-related pathways. Baseline hs-CRP provides a reference point for tracking inflammatory burden over time.
• IGF-1: Relevant to the GHRH-disruption biology associated with HIV wasting and the endocrine context explored in the Mulroney data. Understanding IGF-1 levels provides context for GH-axis function independent of any compound's status.
• Metabolic health markers (fasting glucose, triglycerides): Relevant baseline context for anyone managing HIV-associated metabolic complications, which involve overlapping inflammatory and endocrine pathways. A comprehensive metabolic health baseline covers these markers systematically.

When to Take This Seriously

If you are experiencing neurological symptoms, immune system concerns, or unexplained metabolic changes, those deserve a clinical evaluation — not an investigation of an investigational compound that failed its principal clinical trial. The appropriate pathway for HIV-related neurological concerns is evaluation by an infectious disease or neurology specialist who can assess CD4 count, viral load, and standard neuropsychological markers in context.

The biological questions that motivated Peptide T research — how inflammation damages the nervous system, how CCR5 signaling contributes to neurological disease, and how immune activation relates to cognitive function — remain clinically important and are increasingly tractable through standard testing. That commitment to data before decisions is at the center of what Superpower does — the understanding that knowing your biology is the starting point for every health decision, not a footnote to it.

Important Safety Information

Peptide T (DAPTA) is not FDA-approved for any indication as of April 2026. It is not listed on the FDA's bulk drug substances list for compounding under Section 503A and is not available through licensed compounding pharmacies in the United States. Superpower Health does not prescribe, sell, or facilitate access to Peptide T.

The randomized controlled trials completed for Peptide T in HIV-associated cognitive impairment did not meet primary efficacy endpoints. Clinical safety data from these trials showed an absence of significant adverse effects at the doses studied, but no comprehensive long-term safety profile exists. Products sold as Peptide T through unregulated online sources have not been evaluated for identity, purity, or safety.

This article is provided for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment guidance. Consult a qualified healthcare provider before making any health decisions.

Disclaimer: Peptide T (DAPTA) is not FDA-approved for any indication as of April 2026. This page is provided for educational and informational purposes only. Superpower does not prescribe, sell, or facilitate access to Peptide T.